Psychedelics aren’t fully mainstream yet, but they’re no longer on the fringe. Research headlines are becoming more frequent, public conversation is less hushed, and commercial interest is no longer confined to underground or academic spaces.
Even without widespread legalisation, psychedelics are already being reframed as therapies, tools for insight, and as solutions to burnout, depression, and disconnection. The shift is underway, shaping expectations and demand long before formal systems are in place.
This stage matters more than it might seem. Mainstreaming doesn’t begin with policy. It begins with culture. The stories we tell, the language we use, and the models we build early on tend to outlast the regulations that eventually follow.
Cannabis offers a clear example of this. Long before legalisation expanded access, cannabis moved through a quieter transformation: from taboo to therapeutic, from medicine to wellness product, from social movement to commercial industry. By the time laws caught up, many of the industry’s core structures were already set.
Psychedelics are now entering a similar moment, but under different conditions and with higher stakes. Cannabis shows how quickly care-first intentions can be overtaken once markets form, and how difficult it is to course-correct after systems harden.
The question isn’t whether psychedelics will move toward broader acceptance. That trajectory is already visible. The real question is what gets built in the process, and whether the lessons from cannabis are applied early enough to matter, before the shape of the system becomes difficult to change.
Table of Contents:
- Cannabis Shows That Commodification Starts Long Before Legalisation
- What “Going Mainstream” Actually Looks Like
- How Cannabis Lost the Plot
- Psychedelics Are Entering the Early Stages of the Pipeline
- Where the Cannabis Comparison Breaks Down
- What Psychedelic Commercialisation Could Make Possible
- What the Cannabis Industry Can Teach Us Moving Forward
Cannabis Shows That Commodification Starts Long Before Legalisation
Long before adult-use markets opened, cannabis moved through a gradual but recognisable arc—one shaped less by policy than by cultural reframing, medical legitimacy, and early commercial opportunity.
From Criminalisation to Cultural Persistence
For much of the 20th century, cannabis was criminalised across large parts of the world, framed as a social threat and aggressively policed under prohibition-era drug policy. In the United States, this took the form of the War on Drugs; elsewhere, colonial and postcolonial legal systems imposed similar restrictions.
Despite this, cannabis maintained cultural footholds globally. It continued to be used in religious, medicinal, and social contexts in places such as Jamaica, India, Morocco, and parts of Africa, often alongside (or in quiet defiance of) formal law. These uses didn’t translate into legal protection, but they preserved knowledge, demand, and cultural familiarity long before markets existed.
Medical Legitimacy as the First Turning Point
The first major shift came from medicine. In the 1980s and 1990s, activists and patients pushed cannabis into public view as a tool for compassionate care. It was used to stimulate appetite, manage pain, and reduce nausea when few alternatives were available.
These efforts led to early medical cannabis programs, most notably California’s 1996 legalisation of medical marijuana. While access remained limited and highly regulated, the impact on public perception was significant. Cannabis was no longer discussed solely as an illicit substance; it was increasingly framed as therapeutic.
Medical legitimacy also facilitated research and pharmaceutical interest. Synthetic THC medications entered the market, and countries like Israel and Canada began developing structured cannabinoid research and medical access programs. These systems were imperfect and restrictive, but they shifted the narrative from criminality to clinical use.
The Shift from Medicine to Wellness
As medical use of cannabis normalised cannabis in public discourse, wellness marketing reframed it for broader audiences. Products emphasising “relief without intoxication” expanded cannabis beyond patient populations to everyday consumers. CBD became the centrepiece of this transition, positioning cannabis as a functional ingredient for stress, sleep, inflammation, and skincare.
This shift accelerated well before comprehensive legalisation. In the years leading up to the 2018 U.S. Farm Bill, CBD products were already widely available online and in retail outlets across the U.S., the UK, and Europe, often operating in regulatory grey areas as consumer interest surged. The substance became familiar, accessible, and normalised long before the legal landscape was settled.
Lifestyle Branding and Early Market Formation
By the time laws began to catch up, markets were already forming. Branding, influencer marketing, and lifestyle positioning transformed cannabis into a consumer category. Dispensaries became curated retail environments. New formats such as edibles, beverages, tinctures, topicals, and others expanded appeal and reach.
In many regions, particularly where regulation lagged behind demand, the product arrived before the policy. Legalisation didn’t create the market so much as formalise systems that were already taking shape.
What This Timeline Reveals
Cannabis did not move directly from illegality to a regulated industry. It moved from stigma to medicine, from medicine to wellness, and from wellness to lifestyle branding, with each step increasing cultural comfort and commercial viability.
What cannabis demonstrates, across markets and borders, is that commodification begins long before legalisation. By the time laws are written, narratives are often entrenched, consumer expectations are set, and economic incentives are already in motion. Once those structures solidify, they become difficult to reshape.
Psychedelics are not yet where cannabis was in the 2010s, but they are approaching the same early inflexion point. Understanding how cannabis moved through this pre-legal phase helps clarify why the framing choices being made now will matter far more than any single policy decision later.
What “Going Mainstream” Actually Looks Like
Mainstreaming is often treated as a finish line. Something that happens once a substance becomes legal, regulated, or widely accepted. But in reality, it’s a pipeline. The most consequential shifts happen long before policy changes, shaped by how a substance is framed, simplified, and made culturally legible.
Cannabis illustrates this clearly. Its transformation wasn’t driven by a single law or market opening, but by a sequence of reinforcing steps that built momentum well ahead of regulation.
Mainstreaming Functions as a Pipeline
Rather than a moment, mainstreaming operates as a progression:
Curiosity → legitimacy → simplification → scalability → regulatory capture
What matters is not just the order of these stages, but how each one feeds the next.
Curiosity → Legitimacy
Cannabis began as taboo, associated with counterculture and social resistance. Medical use reframed it as legitimate—particularly when it became visible as a tool for AIDS patients and others with unmet medical needs.
Legitimacy → Simplification
That legitimacy invited broader curiosity: if this substance could support appetite, pain, sleep, and inflammation, perhaps it had wider relevance. Wellness narratives expanded that idea further, positioning cannabis as natural, versatile, and broadly supportive of the body.
Simplification → Scalability
As interest grew, businesses followed. Commercial investment funded research, marketing, and product development, reinforcing a simplified message: this plant can do a lot, and it’s accessible to many. That message generated positive press, normalised experimentation, and widened demand.
Scalability → Regulatory Capture
New formats emerged to meet that demand, each lowering the barrier to entry for a new kind of consumer. Over time, visibility compounded. Cannabis appeared on television, in music, advertising, and everyday conversation. It became familiar enough that it no longer required explanation.
This is what cultural normalisation looks like in practice: not a sudden shift, but an accumulation of exposure.
Why Simplification Enables Momentum
For a substance to move beyond niche or medical contexts, it has to be easy to talk about. That pressure favours simplified narratives, offering clear benefits, broad applicability, and minimal friction for newcomers.
Simplification makes substances easier to understand, share, and integrate into daily life. It also makes them easier to scale. As these narratives circulate, they shape interest and demand well before formal systems are in place to support widespread use.
Where Psychedelics Are in This Process
Psychedelics are now moving through this same cultural pipeline. Once treated as untouchable, they’re increasingly framed through curiosity, spirituality, creativity, and therapeutic promise. References appear in films and TV shows, music, and popular media. Research headlines and conference talks lend legitimacy. Businesses and startups enter the space, funding studies and shaping public-facing language.
As with cannabis, simplified narratives make psychedelics feel more approachable: tools for insight, growth, or optimisation rather than substances that require context, screening, or support. The result is growing interest and visibility, even as access remains limited and infrastructure uneven.
What’s unfolding now is normalisation. Psychedelics are becoming familiar, discussable, and culturally legible. As cannabis shows, this conversation stage is where expectations form and momentum builds, long before formal systems are fully defined.
How Cannabis Lost the Plot
Before cannabis became a global industry, it was framed as a corrective to prohibition, to harm, to exclusion. Legalisation efforts weren’t just about access; they were about repair. Cannabis was positioned as a way to reduce the damage of criminalisation, centre patient care, and create economic opportunity for communities that had borne the brunt of enforcement.
Those promises mattered. And in many cases, they were sincere.
The Promises Cannabis Made
Across markets, legalisation was tied to a set of recurring goals:
- Patient access and safety through regulated medical use
- Credible medical legitimacy backed by research and oversight
- Social equity and repair, particularly for communities harmed by prohibition
- Small business opportunity and pathways for legacy operators
- Reduced harm through decriminalisation and regulated access
These ideas weren’t fringe talking points, but central to how cannabis was sold to the public and policymakers alike. Legalisation was framed as both progress and a moral and social good.
Why Those Promises Didn’t Fully Materialise
As cannabis moved through the commercialisation pipeline, those early goals began to compete with a different set of incentives.
High capital requirements, complex licensing systems, and uneven enforcement created barriers that favoured well-funded entrants over small operators. Equity programs (where they existed) were often under-resourced, slow to implement, or burdened with requirements that made participation difficult. In many regions, criminalisation persisted under new forms, even as legal markets expanded alongside them.
At the same time, the public narrative shifted. Education gave way to marketing. Broad wellness claims replaced medical nuance. Branding became the primary interface between the substance and the public, concentrating narrative control in the hands of companies best positioned to scale quickly.
Legalisation accelerated competition faster than it corrected structural inequities. The market rewarded speed, visibility, and volume, not necessarily care, context, or community repair. Over time, cannabis became what the system incentivised it to be.
This wasn’t the result of a single failure or bad actor. It was the outcome of early design choices colliding with market pressure. Once the industry scaled, those pressures were difficult to resist and even harder to reverse.
Why This Matters for Psychedelics
Psychedelics are now entering the public conversation under similarly ambitious language: healing, access, transformation, and justice. These goals are compelling, and they’re not inherently incompatible with broader acceptance.
But cannabis shows that good intentions alone aren’t enough. Without deliberate structural support, early promises can erode as markets expand and narratives simplify. When growth outpaces care, the values that sparked mainstream interest can be sidelined by the systems built to sustain demand.
Psychedelics are earlier in this process. The outcomes are not yet fixed. But the pressures that reshaped cannabis (capital concentration, narrative capture, and speed-over-structure) are already visible. Understanding where cannabis drifted helps clarify what’s at risk if those forces go unexamined.
Psychedelics Are Entering the Early Stages of the Pipeline
Psychedelics are not yet widely legal or accessible, but they are already moving through the earliest stages of mainstreaming. As cannabis demonstrated, this process begins well before regulation, with curiosity, legitimacy, and simplified framing shaping public perception ahead of formal systems.
Curiosity: From Taboo to Cultural Interest
For decades, psychedelics were largely treated as untouchable and associated with counterculture, legal risk, and moral panic. That framing has softened. Curiosity has re-emerged from multiple directions at once: anecdotal users sharing personal experiences, interest in natural and alternative medicine, and renewed attention to spiritual and ceremonial use in non-Western cultures.
At the same time, psychedelics are appearing more frequently in mainstream media. References in films, television, music, and podcasts have reframed them as intriguing rather than dangerous. Curiosity no longer requires subcultural fluency. Psychedelics are becoming something people can openly wonder about, ask questions about, and imagine for themselves.
Legitimacy: Medicine, Therapy, and Guided Experience
Curiosity alone doesn’t move substances forward; legitimacy does. In recent years, psychedelic research has expanded into the medical field, with studies exploring applications for treatment-resistant depression, PTSD, addiction, and cluster headaches. These findings have shifted psychedelics from speculative interest into serious scientific conversation.
That legitimacy has created space for early access models. In some countries and regions, looser cultural or legal frameworks have allowed psychedelic retreats (often centred around ayahuasca or psilocybin) to operate openly. These experiences are typically expensive, highly curated, and located in scenic settings, blending therapeutic language with spiritual framing and luxury wellness aesthetics.
In parallel, clinical models are beginning to form. Ketamine therapy is already available in regulated medical settings, and therapist-guided psilocybin models are emerging where permitted. While these approaches haven’t reached mass adoption, their existence signals an important shift: psychedelics are no longer only cultural curiosities. They’re also being positioned as legitimate therapeutic tools.
Simplification: From Contextual Use to Lifestyle Language
Alongside legitimacy, simplification has begun to take hold. Psychedelics are increasingly framed as tools for productivity, creativity, and self-optimisation, especially through microdosing discourse. As with early cannabis wellness narratives, emphasis is placed on subtle benefits and everyday integration rather than intensity, context, or risk.
This framing makes psychedelics feel approachable. It also abstracts them from the conditions that shape their effects. Microdosing, biohacking language, and performance-oriented messaging position psychedelics as enhancements rather than experiences that require preparation, support, or follow-through.
As these simplified narratives circulate, psychedelics become easier to talk about, easier to imagine using, and easier to package within broader wellness ecosystems alongside other wellness-centred ideals like breathwork, cold plunges, and optimisation culture.
Where This Leaves the Conversation
Together, these shifts place psychedelics firmly within the early stages of the mainstreaming pipeline. Curiosity is growing. Legitimacy is forming. Simplified language is widening its appeal. Even without broad legalisation, the cultural groundwork is being laid.
This is the same phase cannabis occupied before markets fully formed. The next stages (scale, structure, and consolidation) have not yet arrived. But the direction of movement is already visible.
Where the Cannabis Comparison Breaks Down
Cannabis offers a useful lens for understanding how substances move toward mainstream acceptance, but it is not a perfect comparison. At a certain point, the analogy breaks down, and that distinction matters.
Cannabis is generally understood as low-risk for most adults when used regularly. Its effects are familiar, relatively short-lived, and easy to moderate. That made it possible to normalise cannabis as a daily-use product, expand into many formats, and scale access quickly without fundamentally changing how people thought about safety.
But psychedelics are different.
Their effects are not subtle or routine. They can be psychologically intense, highly subjective, and deeply shaped by mindset, environment, and support. Even as they become more culturally visible, psychedelics cannot be treated as interchangeable with cannabis or approached with the same casual assumptions.
As psychedelics move through early normalisation, there is a growing risk that familiarity will be mistaken for safety. Simplified language, positive media coverage, and wellness framing can make them feel comparable to cannabis, but that comparison is misleading. Where cannabis could scale through consumer choice and product variety, psychedelics demand a different level of care. Screening, preparation, context, and follow-through are not optional but central to how these substances function.
For that reason, psychedelics cannot scale the way cannabis did. Daily-use models, mass consumer formats, and frictionless access are neither realistic nor responsible paths forward. At the same time, growing legitimacy brings its own pressures. As research expands and businesses invest, studies can be funded to support particular narratives, just as they were in cannabis. Without guardrails, simplified messaging can outpace nuance, and public understanding can lag behind real risk.
Broader acceptance for psychedelics will require protections for ceremonial and religious use, more thoughtful access pathways, clearer public education, and safeguards that account for psychological intensity, not just physical safety.
Normalisation does not have to mean casualisation. Recognising that difference early is what allows psychedelics to be approached thoughtfully, rather than treated like something they are not.
What Psychedelic Commercialisation Could Make Possible
So far, the cannabis story has offered plenty of cautionary lessons: about early framing, about lost intentions, about what gets sidelined when scale becomes the goal. But commercialisation isn’t inherently the problem. In many cases, it’s what makes progress possible by funding research, expanding access, and building systems that underground networks alone can’t always support.
The question isn’t whether psychedelics will be commercialised. That process is already underway. The question is how commercialisation unfolds, and whether it reinforces the values that sparked this resurgence or quietly erases them.
Done right, commercialisation could expand access, build legitimacy, and support a more thoughtful infrastructure for psychedelic care. Unlike cannabis, psychedelics are early enough in the curve that some of these outcomes are still adjustable.
Access Beyond the Underground
Underground and informal psychedelic networks have sustained use for decades through community ceremonies, peer-led journeys, retreat spaces, and quiet therapeutic circles. These systems carry immense cultural value and have provided meaningful support, often in the absence of legal alternatives.
But they also have limitations. Access is often restricted to those with the right connections, cultural capital, or geographic proximity. Legal risks persist. And for many people (especially those with health concerns, trauma histories, or limited social support) exploring psychedelics outside a structured setting can feel unsafe or simply out of reach.
Commercialisation could help bridge that gap. Regulated models can reduce stigma and open doors for people who would never seek out underground or ceremonial use. Clinical settings (though imperfect) can offer screening, supervision, and integration support that make these experiences more accessible to broader populations.
Cannabis showed that cultural legitimacy expands reach, but only when cost, location, and gatekeeping aren’t the new barriers. Psychedelic infrastructure still has time to avoid those traps. Legalisation alone isn’t enough. Access also needs to be designed with intention.
Research, Funding, and Medical Legitimacy
One of the strongest cases for commercialisation is its ability to fund what would otherwise stall: clinical trials, safety data, dosing research, and long-term studies that help move psychedelics out of speculation and into structured care.
We’re already seeing this play out. Studies on psilocybin, MDMA, and ketamine are gaining traction in medical journals. Research groups, startups, and nonprofit coalitions are working to understand therapeutic applications for depression, PTSD, addiction, cluster headaches, and more. In many countries, these studies are only possible because commercial or philanthropic funding is backing the work.
Cannabis showed this first. Without widespread decriminalisation and public pressure, most of the medical research we have today wouldn’t exist. Commercial interest accelerated what governments were slow to prioritise. That interest wasn’t always neutral; it often steered research toward marketable outcomes. But without it, there wouldn’t have been a foothold for evidence-based cannabis medicine at all.
That’s the tradeoff. Capital brings momentum, but it also brings an agenda. In cannabis, we saw how funding could skew the research narrative, highlighting consumer-friendly effects while overlooking long-term questions or underserved populations. Psychedelics are vulnerable to the same dynamic. If research is driven mostly by what’s profitable, it risks overlooking what’s culturally or clinically essential.
Still, the potential here is real. With the right checks (transparency, community involvement, ethical review, etc.), commercial funding can push research further, faster. Cannabis struggled to strike that balance. Psychedelics still have time to build it from the ground up.
Building Infrastructure Instead of Hype
Cannabis scaled quickly. Public curiosity and commercial interest outpaced the systems needed to support safe, informed use. Education, regulation, product testing, and access equity were treated as afterthoughts in many markets. That infrastructure gap created confusion, inconsistent experiences, and unequal outcomes, especially for the people legalisation was supposed to serve.
Psychedelics still have a chance to avoid that. But only if the foundation gets built before mass commercialisation locks into place.
That means doing the unglamorous work early:
- Establishing clear contraindications and screening protocols
- Training facilitators and therapists across diverse models
- Funding integration support and long-term follow-up
- Creating room for multiple pathways (not just clinical, but also community-led, ceremonial, and peer-supported)
None of this is as headline-worthy as “breakthrough therapy” or “mental health revolution.” But it’s what makes those headlines real. Without infrastructure, the promise of healing becomes just another brand message.
Cannabis showed how easily systems default to profit when care isn’t designed into the foundation. Psychedelics may never be risk-free, but they can be handled responsibly if we treat care not as a marketing buzzword, but as a structure.
What the Cannabis Industry Can Teach Us Moving Forward
Psychedelics are beginning to follow a familiar path. As with cannabis, curiosity has softened stigma, legitimacy has expanded interest, and simplified narratives are making these substances feel increasingly approachable. That resemblance is useful, but only up to a point.
Cannabis and psychedelics are not interchangeable, and they were never going to be. The substances differ in intensity, context, and risk, which means the way they move into the mainstream cannot be one-to-one. Recognising that difference early is what makes thoughtful progress possible.
The opportunity now is not to resist progress, but to apply what’s already been learned: to scale access without flattening complexity, to fund research without overstating certainty, and to professionalise care without erasing culture or tradition. Cannabis shows how quickly early framing can shape everything that follows. Psychedelics are still early enough that those choices remain open.
The question isn’t whether psychedelics will move toward broader acceptance. That momentum is already underway. The question is whether the structures built around them reflect what cannabis has already taught us before those structures become permanent.
Leave a Comment